1. Retsch-Bogart GZ, Quittner AL, Gibson RL, et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest. 2009;135(5):1223-1232.

  2. McCoy KS, Quittner AL, Oermann CM, et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med. 2008;178(9):921-928.

  3. Oermann CM, Retsch-Bogart GZ, Quittner AL, et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol. 2010;45(11):1121-1134.

  4. US Food and Drug Administration. Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Washington, DC: US Food and Drug Administration; 2009.

  5. Data on file, Gilead Sciences, Inc. 2007.

  6. American Thoracic Society. Cystic Fibrosis Questionnaire (CFQ); Cystic Fibrosis Questionnaire Revised (CFQ-R). Accessed June 13, 2019. /cfq-cfq-r.html

  7. CFQ-R - Questionnaire (Adolescents/Adults). Version 1.0, April 19, 2005.

  8. Assael BM, Pressler T, Bilton D, et al. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. J Cyst Fibros. 2013;12(2):130-140.

  9. CAYSTON. Prescribing information. Gilead Sciences; 2019. Accessed April 17, 2020. /respiratory/cayston/cayston_pi.pdf

  10. Altera Nebulizer System Instructions for Use. PARI Respiratory Equipment, Inc.; 2010.